var title_f4_36_4672="Regulation ferritin and TfR";
var content_f4_36_4672=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F56268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F56268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 577px\">",
"   <div class=\"ttl\">",
"    Regulation of transferrin receptor and ferritin synthesis by iron",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 557px; height: 343px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representations of the regulation of transferrin receptor and ferritin synthesis through translational controls operated by the iron-responsive elements (IREs) and the iron regulatory proteins IRP1 and IRP2. Only one IRE (spike-like structures shown on accompanying diagrams) is present in the 5'-untranslated region (UTR) of ferritin mRNA, which is shown on the two diagrams on the left. When cellular iron is scarce (upper left diagram), iron regulatory protein (IRP) molecules (shown as the pac-man-like circles) are available for binding the 5' IRE; initiation of translation is prevented; and ferritin synthesis is inhibited. By contrast, presence of abundant intracellular iron prevents binding of IRPs to the 5' IRE (lower left) and allows efficient mRNA translation to proceed through the open reading frame (ORF, green arrow). Five IREs are present in the 3'-UTR of transferrin receptor (TfR) mRNA, shown on the two diagrams on the right. When cellular iron is scarce (upper right), binding of one or more IRPs to the IREs in the 3'-UTR stabilizes TfR mRNA and increases TfR translation. Conversely, when iron is abundant (right lower diagram), very few IREs are occupied by IRPs, and TfR mRNA is rapidly degraded.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cazzola, M, Skoda, RC. Translational pathophysiology: a novel molecular mechanism of human disease. Blood 2000; 95:3280. Copyright &copy;2000 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_36_4672=[""].join("\n");
var outline_f4_36_4672=null;
var title_f4_36_4673="Bipartite medial sesamoid";
var content_f4_36_4673=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Bipartite medial (tibial) sesamoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the rounded corners and smooth contours of each of the two pieces of this sesamoid, best seen in panel A (white arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_36_4673=[""].join("\n");
var outline_f4_36_4673=null;
var title_f4_36_4674="Popliteal angle";
var content_f4_36_4674=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Popliteal angle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 415px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The popliteal angle is a measure of hamstring flexibility. With the patient relaxed and supine, flex the knee to 90 degrees, then gently extend the lower leg until you appreciate resistance. The angle of the leg at this point is the popliteal angle and is an objective measure of hamstring flexibility.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_36_4674=[""].join("\n");
var outline_f4_36_4674=null;
var title_f4_36_4675="Icatibant: Drug information";
var content_f4_36_4675=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Icatibant: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/32/34307?source=see_link\">",
"    see \"Icatibant: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13206139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Firazyr&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13203885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Selective Bradykinin B",
"      <sub>",
"       2",
"      </sub>",
"      Receptor Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13206200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hereditary angioedema (HAE): SubQ: 30 mg/dose; may repeat one dose every 6 hours if response is inadequate or symptoms recur (maximum: 3 doses/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F13206201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Systemic exposure may be increased; however, no dosage adjustments are recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13206203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustments are recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13206202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustments are recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13206140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Firazyr&reg;: 10 mg/mL (3 mL)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13206204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For SubQ injection only. Inject into the abdomen over &ge;30 seconds, using the 25 gauge  needle provided. Inject 2-4 inches below belly button and away from any scars; do not inject into an area that is bruised, swollen, or painful.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13203852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute attacks of hereditary angioedema (HAE)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13206165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Local: Injection site reaction (97%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Pyrexia (4%), dizziness (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Transaminase increased (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Anti-icatibant antibody production (no association with efficacy observed), headache, nausea, rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13206161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13206162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Airway obstruction: Airway obstruction may occur during acute laryngeal attacks of HAE. Patients with laryngeal attacks should be instructed to seek medical attention immediately in addition to treatment with icatibant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; ACE inhibitors: Icatibant may potentially attenuate the antihypertensive effect of ACE inhibitors; patients taking ACE inhibitors were excluded from initial clinical trials.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13225901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Icatibant may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13206158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13206159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies with doses close to or less than the recommended human dose.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13206160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Firazyr Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/3 mL (3 mL): $8853.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13206206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptom relief; laryngeal symptoms or airway obstruction (immediate medical attention required in addition to icatibant therapy)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13276714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Firazyr (AT, AU, BE, CH, CZ, DE, DK, EE, FR, GB, GR, IE, IL, NL, NO, PL, PT, RU, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13206180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Icatibant is a selective competitive antagonist for the bradykinin B",
"     <sub>",
"      2",
"     </sub>",
"     receptor. Patients with HAE have an absence or dysfunction of C1-esterase-inhibitor which leads to the production of bradykinin. The presence of bradykinin may cause symptoms of localized swelling, inflammation, and pain. Icatibant inhibits bradykinin from binding at the B",
"     <sub>",
"      2",
"     </sub>",
"     receptor, thereby treating the symptoms associated with acute attack.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13206182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset: Median time to 50% decrease of symptoms: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Inhibits symptoms caused by bradykinin for ~6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 20.3-37.7 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Metabolized by proteolytic enzymes to metabolites (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: ~97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 1-1.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 0.75 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (&lt;10% unchanged)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cicardi M, Banerji A, Bracho F, et al, \"Icatibant, A New Bradykinin-Receptor Antagonist in Hereditary Angioedema,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 363(6):532-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/36/4675/abstract-text/20818888/pubmed\" id=\"20818888\" target=\"_blank\">",
"        20818888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16808 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-7920B88E07-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_36_4675=[""].join("\n");
var outline_f4_36_4675=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206139\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203885\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206200\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206201\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206203\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206202\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206140\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206204\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203852\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206165\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206161\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206162\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299506\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13225901\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206158\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206159\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206160\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322916\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206206\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276714\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206180\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206182\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16808\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16808|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/32/34307?source=related_link\">",
"      Icatibant: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_36_4676="Internuclear ophthalmoplegia";
var content_f4_36_4676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F53437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F53437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Internuclear ophthalmoplegia (INO)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 469px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient exhibits a left INO characterized by adduction slowing without ocular limitation. The top picture (A) depicts the patient in a primary gaze position, while the bottom picture (B) depicts the point at which the right eye reaches a 20 degree target while saccading to the right. Note that the right eye reaches the target prior to the left eye, as demonstrated with the midpupillary markers shown. (Note that the left eye has not changed position off of the midpupillary marker). At saccade end, both eyes achieve target fixation (as shown in the oculogram).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Frohman EM, O'Suilleabhain P, Dewey RB, et al. A new measure of dysconjugacy in INO: the first-pass amplitude. J Neurol Sci 2003; 210:65. Copyright &copy;2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_36_4676=[""].join("\n");
var outline_f4_36_4676=null;
var title_f4_36_4677="Tizanidine: Patient drug information";
var content_f4_36_4677=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tizanidine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/35/12855?source=see_link\">",
"     see \"Tizanidine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F228405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zanaflex Capsules&reg;;",
"     </li>",
"     <li>",
"      Zanaflex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F228406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Tizanidine&reg;;",
"     </li>",
"     <li>",
"      Gen-Tizanidine;",
"     </li>",
"     <li>",
"      Mylan-Tizanidine;",
"     </li>",
"     <li>",
"      Zanaflex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691274",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to calm muscles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat headaches.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691933",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692115",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat trigeminal neuralgia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tizanidine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697120",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you fall a lot, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697291",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696739",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change from the capsule to the tablet or from the tablet to the capsule.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Always take with food or always take on an empty stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696305",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may sprinkle contents of capsule on applesauce. Do not chew.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11098 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-3AAB480B33-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_36_4677=[""].join("\n");
var outline_f4_36_4677=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228405\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228406\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028395\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028397\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028396\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028401\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028402\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028404\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028399\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028400\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028405\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028406\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/35/12855?source=related_link\">",
"      Tizanidine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_36_4678="AJCC diagram of the esophageal anatomy";
var content_f4_36_4678=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    AJCC regions of the esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 659px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The American Joint Committee on Cancer (AJCC) divides the esophagus into four areas. The cervical esophagus extends from the lower border of the cricoid cartilage to the thoracic inlet. The upper thoracic esophagus extends from the thoracic inlet to the tracheal bifurcation. The mid-thoracic esophagus extends from the tracheal bifurcation to a level approximately 32 cm from the incisors. The lower thoracic and abdominal esophagus extends from the mid-thoracic esophagus to the EG junction, approximately 40 cm from the incisors.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <em>",
"      Data from: Esophagus. In: AJCC Cancer Staging Manual, 6th edition, 2002.",
"     </em>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_36_4678=[""].join("\n");
var outline_f4_36_4678=null;
var title_f4_36_4679="Chlordiazepoxide: Drug information";
var content_f4_36_4679=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chlordiazepoxide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/40/33412?source=see_link\">",
"    see \"Chlordiazepoxide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F149577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Benzodiazepine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F149543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anxiety:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Mild-moderate anxiety:",
"     </i>",
"     Usual daily dose: 5-10 mg 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Severe anxiety:",
"     </i>",
"     Usual daily dose: 20-25 mg 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Preoperative anxiety:",
"     </b>",
"     Oral: 5-10 mg 3-4 times/day on the days preceding surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ethanol withdrawal symptoms:",
"     </b>",
"     Oral: 50-100 mg to start; dose may be repeated in 2-4 hours as necessary to a maximum of 300 mg/24 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Frequency of repeat doses is often based on institution-specific protocols.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F149558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Anxiety:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &lt;6 years: Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;6 years: Anxiety: Usual daily dose: 5 mg 2-4 times/day. Dose may be increased to 10 mg 2-3 times/day in some patients, if necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F149544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: 5 mg 2-4 times/day. Avoid use if possible due to long-acting metabolite.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F149545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Dosage adjustments are not provided in the manufacturer&rsquo;s labeling; however, the following guidelines have been used by some clinicians (Aronoff, 2007): Adults: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Peritoneal dialysis: Administer 50% of the dose.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F149546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no specific hepatic dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution or avoid use in hepatic impairment; hepatic metabolism occurs.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F149512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 5 mg, 10 mg, 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F149496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F149579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F149517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Administer orally in divided doses.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F149516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of anxiety disorder or for the short-term relief of symptoms of anxiety; withdrawal symptoms of acute alcoholism; preoperative apprehension and anxiety",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F149587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ChlordiazePOXIDE may be confused with chlorproMAZINE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Librium may be confused with Librax&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F149575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Drowsiness, fatigue, ataxia, lightheadedness, memory impairment, dysarthria, irritability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased, menstrual disorders",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia, salivation decreased, appetite increased or decreased, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Micturition difficulties",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Confusion, dizziness, disinhibition, akathisia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dermatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Salivation increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Sexual dysfunction, incontinence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Rigidity, tremor, muscle cramps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Photosensitivity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F149520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chlordiazepoxide or any component of the formulation (cross-sensitivity with other benzodiazepines may also exist)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F149500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use caution in patients with depression, particularly if suicidal risk may be present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impaired gag reflex: Use with caution in patients with an impaired gag reflex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants/psychoactive medications: Use with caution in patients receiving other CNS depressants or psychoactive medication; effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; active metabolites with extended half-lives may lead to delayed accumulation and adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: In older adults, benzodiazepines increase the risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents. Due to increased sensitivity in this age group and slower metabolism of long-acting agents (such as chlordiazepoxide), avoid use for treatment of insomnia, agitation, or delirium (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in children; active metabolites with extended half-lives may lead to delayed accumulation and adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Rebound or withdrawal symptoms may occur following abrupt discontinuation or large decreases in dose. Use caution when reducing dose or withdrawing therapy; decrease slowly and monitor for withdrawal symptoms. Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F149572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F149505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Benzodiazepines (metabolized by oxidation). Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May increase the serum concentration of ChlordiazePOXIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation). Specifically, the active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F149534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Serum concentrations/effects may be increased with grapefruit juice, but unlikely because of high oral bioavailability of chlordiazepoxide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11228990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Chlordiazepoxide crosses the human placenta and fetal serum concentrations are similar to those in the mother. Teratogenic effects have been observed with some benzodiazepines (including chlordiazepoxide); however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) has been reported with some benzodiazepines.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F149549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F149524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drowsiness, lethargy, or weight loss in nursing infants have been observed in case reports following maternal use of some benzodiazepines.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F149523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (ChlordiazePOXIDE HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $31.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $35.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $38.51",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F149509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory and cardiovascular status, mental status, check for orthostasis",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F149513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: 0.1-3 mcg/mL (SI: 0-10 micromole/L); Toxic: &gt;23 mcg/mL (SI: &gt;77 micromole/L)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F149525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Benpine (MY, SG, TH);",
"     </li>",
"     <li>",
"      Cetabrium (ID);",
"     </li>",
"     <li>",
"      Chlordiazepoxid L.F.M. (HU);",
"     </li>",
"     <li>",
"      Chlordiazepoxidum (NL);",
"     </li>",
"     <li>",
"      Cozep (TH);",
"     </li>",
"     <li>",
"      Elenium (BG, CZ, HN, HU, PK, PL, RU);",
"     </li>",
"     <li>",
"      Eposal (VE);",
"     </li>",
"     <li>",
"      Equilibrium (IN);",
"     </li>",
"     <li>",
"      Klopoxid (DK);",
"     </li>",
"     <li>",
"      Klorpo (PH, SG);",
"     </li>",
"     <li>",
"      Liberty (KP);",
"     </li>",
"     <li>",
"      Librium (AE, BH, CY, EG, FR, GB, GH, HK, HN, HU, ID, IE, IN, IQ, IR, IT, JO, KE, KW, LB, LY, OM, QA, SA, SG, SY, TZ, UG, YE, ZA, ZM);",
"     </li>",
"     <li>",
"      Libulin (TW);",
"     </li>",
"     <li>",
"      Nova-Pam (NZ);",
"     </li>",
"     <li>",
"      O.C.M. (AR);",
"     </li>",
"     <li>",
"      Oasil (GR);",
"     </li>",
"     <li>",
"      Omnalio (ES);",
"     </li>",
"     <li>",
"      Paxium (PT);",
"     </li>",
"     <li>",
"      Peast C (JP);",
"     </li>",
"     <li>",
"      Psicosedin (BR);",
"     </li>",
"     <li>",
"      Radepur (AE, BH, CY, DE, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Retcol (JP);",
"     </li>",
"     <li>",
"      Risolid (DK, FI);",
"     </li>",
"     <li>",
"      Seren (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Sophiamin (JP);",
"     </li>",
"     <li>",
"      Trakipearl (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F149499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F149519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 90% to 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic to desmethyldiazepam (active and long-acting)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 6.6-25 hours; End-stage renal disease: 5-30 hours; Cirrhosis: 30-63 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (minimal as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/36/4679/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/36/4679/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bergman U, Rosa FW, Baum C, et al, \"Effects of Exposure to Benzodiazepine During Fetal Life,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1992, 340(8821):694-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/36/4679/abstract-text/1355799/pubmed\" id=\"1355799\" target=\"_blank\">",
"        1355799",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burkhart KK and Kulig KW, &ldquo;The Diagnostic Utility of Flumazenil (a Benzodiazepine Antagonist) in Coma of Unknown Etiology,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1990, 19(3):319-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/36/4679/abstract-text/2106810/pubmed\" id=\"2106810\" target=\"_blank\">",
"        2106810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hicks R, Dysken MW, Davis JM, et al, &ldquo;The Pharmacokinetics of Psychotropic Medication in the Elderly: A Review,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1981, 42(10):374-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/36/4679/abstract-text/7026541/pubmed\" id=\"7026541\" target=\"_blank\">",
"        7026541",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iqbal MM, Sobhan T, Ryals T, et al, \"Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant,\"",
"      <i>",
"       Psychiatr Serv",
"      </i>",
"      , 2002, 53(1):39-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/36/4679/abstract-text/11773648/pubmed\" id=\"11773648\" target=\"_blank\">",
"        11773648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/36/4679/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wikner BN, Stiller CO, Bergman U, et al, \"Use of Benzodiazepines and Benzodiazepine Receptor Agonists During Pregnancy: Neonatal Outcome and Congenital Malformations,\"",
"      <i>",
"       Pharmacoepidemiol Drug Saf",
"      </i>",
"      , 2007, 16(11):1203-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/36/4679/abstract-text/17894421/pubmed\" id=\"17894421\" target=\"_blank\">",
"        17894421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9243 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-E943584887-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_36_4679=[""].join("\n");
var outline_f4_36_4679=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149577\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149543\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149558\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149544\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149545\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149546\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149512\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149496\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149579\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149517\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149516\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149587\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149575\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149520\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149500\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149572\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149505\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149534\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11228990\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149549\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149524\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149523\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149509\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149513\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149525\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149499\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149519\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9243\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9243|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/40/33412?source=related_link\">",
"      Chlordiazepoxide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_36_4680="Mastitis and breast abscess in infants, children, and adolescents";
var content_f4_36_4680=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mastitis and breast abscess in infants, children, and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/36/4680/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/36/4680/contributors\">",
"     Chantay Banikarim, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/36/4680/contributors\">",
"     Nirupama K De Silva, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/36/4680/contributors\">",
"     R&eacute;gine Fortunov, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/36/4680/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/36/4680/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/36/4680/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/36/4680/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/36/4680/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/36/4680/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/36/4680/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overview of mastitis and breast abscess in infants, children, and nonlactating adolescents will be presented below. Breast infections in lactating women and adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/28/454?source=see_link\">",
"     \"Lactational mastitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9495?source=see_link\">",
"     \"Breast abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND PREDISPOSING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast infection (mastitis or breast abscess) typically occurs in infants younger than two months of age (neonatal mastitis) and lactating women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/1-6\">",
"     1-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the first two weeks of life, neonatal mastitis occurs with equal frequency in girls and boys [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Thereafter, it is more common in girls, with a female:male ratio of approximately 2:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/3\">",
"     3",
"    </a>",
"    ]. This is thought to be related to the longer duration of physiologic breast hypertrophy in female than in male infants [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/3\">",
"     3",
"    </a>",
"    ]. Maternal skin or soft-tissue infection in the postpartum period may be associated with neonatal mastitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Manipulation of the neonatal breast to express a clear or cloudy (milk-like) nipple discharge (\"witch's milk\") has been considered to be a risk factor for breast abscess, but this finding is not well substantiated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although it is less common than in infants, breast infection also may occur in prepubertal children and",
"    <span class=\"nowrap\">",
"     pubertal/postpubertal",
"    </span>",
"    adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/1,6,10\">",
"     1,6,10",
"    </a>",
"    ]. Factors that predispose to breast infection in children and nonlactating adolescents include trauma (eg, breast manipulation during sexual activity, shaving or plucking periareolar hair, nipple piercing), obesity, mammary duct ectasia, local skin infection, and epidermoid cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/6,10-13\">",
"     6,10-13",
"    </a>",
"    ]. Peripheral mastitis may be associated with diabetes mellitus, rheumatoid arthritis, glucocorticoid therapy, granulomatous disease, and trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neonatal mastitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of cases of neonatal mastitis are caused by",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/1-5,14\">",
"     1-5,14",
"    </a>",
"    ]. Less common causes include gram-negative enteric organisms (eg,",
"    <em>",
"     Escherichia coli",
"    </em>",
"    ,",
"    <em>",
"     Salmonella",
"    </em>",
"    ), anaerobes, and group B streptococcus (",
"    <em>",
"     S. agalactiae",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/1,4,14-18\">",
"     1,4,14-18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     In nonlactational mastitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In older children and adolescents, mastitis is most commonly caused by",
"    <em>",
"     S. aureus",
"    </em>",
"    but may also be caused by",
"    <em>",
"     enterococcus",
"    </em>",
"    ,",
"    <em>",
"     S. pyogenes",
"    </em>",
"    (group A streptococcus), anaerobic streptococci,",
"    <em>",
"     Pseudomonas",
"    </em>",
"    ,",
"    <em>",
"     S. agalactiae",
"    </em>",
"    (group B streptococcus), and",
"    <em>",
"     Bacteroides",
"    </em>",
"    species [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/1,11,13\">",
"     1,11,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of neonatal mastitis is related to the physiologic breast hypertrophy in the term infant, which is induced by maternal hormones, and to the presence of potentially pathogenic bacteria on the skin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mucous membranes that spread to the breast parenchyma through the nipple [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/3,5,19\">",
"     3,5,19",
"    </a>",
"    ]. In addition, bacteria may spread hematogenously to the breast in gram-negative infections or in ill-appearing infants [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/5\">",
"     5",
"    </a>",
"    ]. Nonlactational mastitis results from the introduction of bacteria into the ductal system [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical features of mastitis (regardless of the age of presentation) include swelling, erythema, warmth, tenderness, and induration of the breast [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. Purulent nipple discharge may be present. Breast abscess is indicated by fluctuance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal mastitis typically occurs in full-term infants who are younger than two months. Neonatal mastitis is usually unilateral and local in nature [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Characteristic clinical features include marked erythema, tenderness, and induration of the affected breast bud. Purulent nipple discharge and breast abscess may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The axillary lymph nodes may be enlarged and tender [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/5,20\">",
"     5,20",
"    </a>",
"    ]. One-quarter of patients may also have fever (&gt;101&ordm;F (38.3&ordm;C)). Nearly two-thirds have fluctuance, and approximately one-half have evidence of skin infection at another site (eg, superficial pustules or bullae). The white blood cell (WBC) count can be elevated (&gt;15,000",
"    <span class=\"nowrap\">",
"     WBC/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    in 46 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/3\">",
"     3",
"    </a>",
"    ]. Between 50 and 100 percent of neonatal patients develop abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/5,21\">",
"     5,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic symptoms other than fever (eg, irritability, decreased appetite, vomiting) are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Gastrointestinal symptoms may indicate",
"    <em>",
"     Salmonella",
"    </em>",
"    or other gram-negative enteric pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. Bacteremia is rare (1 to 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/3\">",
"     3",
"    </a>",
"    ]. Significant cerebrospinal (CSF) pleocytosis with sterile CSF culture may be seen in association with mastitis with or without systemic symptoms in patients infected with methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (particularly strain USA300) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/3,22\">",
"     3,22",
"    </a>",
"    ]. Cases of neonatal mastitis complicated by extensive cellulitis, necrotizing fasciitis, and osteomyelitis have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/3,4,23-26\">",
"     3,4,23-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Nonlactational mastitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of mastitis in older children and adolescents are similar to those in neonates: swelling, erythema, warmth, tenderness, and induration of the central or peripheral breast [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. Purulent nipple discharge also may be present. Breast abscess is indicated by fluctuance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Lactational mastitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of mastitis in lactating women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/28/454?source=see_link\">",
"     \"Lactational mastitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of the patient with mastitis should include a careful history and physical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Of neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;In neonates, particular attention should be given to the presence of abscess formation, fever, and other systemic symptoms (eg, poor appetite, lethargy). Although systemic symptoms are uncommon in infants with mastitis, they may indicate a serious infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28074?source=see_link\">",
"     \"Evaluation and management of fever in the neonate and young infant (less than three months of age)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17018?source=see_link\">",
"     \"Approach to the septic-appearing infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the lesion is fluctuant, purulent material from aspiration (with or without ultrasonographic guidance) or incision and drainage also should be sent for Gram stain and culture [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/3,6,22\">",
"     3,6,22",
"    </a>",
"    ]. If incision and drainage are performed, it is important not to injure the underlying breast bud; appropriately trained personnel (eg, a breast surgeon or pediatric gynecologist) should be consulted when this procedure is necessary.",
"   </p>",
"   <p>",
"    In neonates, a complete blood count (CBC) and blood culture should be obtained before the initiation of antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/3,20,22\">",
"     3,20,22",
"    </a>",
"    ]. If present, nipple drainage should be sent for Gram stain and culture (aerobic and anaerobic) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/3,14\">",
"     3,14",
"    </a>",
"    ]. Urine and cerebrospinal fluid cultures should be obtained if these studies are clinically indicated (eg, if the infant is febrile, ill appearing, younger than 28 days of age, or has leukocytosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/3,19,20\">",
"     3,19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28074?source=see_link\">",
"     \"Evaluation and management of fever in the neonate and young infant (less than three months of age)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17018?source=see_link\">",
"     \"Approach to the septic-appearing infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Of nonlactational mastitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In older children and adolescents, the need for WBC count and blood culture depends upon the clinical scenario. In adults with cellulitis, blood cultures are usually of low yield unless the cellulitis is particularly severe [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/27\">",
"     27",
"    </a>",
"    ]. However, a WBC count may be warranted in patients with fever or systemic symptoms, potential abscess, recurrence, or treatment failure. Leukocytosis supports a diagnosis of mastitis, and may be used to follow the clinical course. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are not usually necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link\">",
"     \"Cellulitis and erysipelas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical diagnosis of mastitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    breast abscess can be made in patients with swelling, erythema, warmth, tenderness, induration,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fluctuance of the breast [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. Gram stain and cultures confirm the diagnosis and direct antimicrobial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In neonates, it is important to distinguish mastitis from physiologic breast hypertrophy, which resolves spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/28\">",
"     28",
"    </a>",
"    ]. In contrast to mastitis, in physiologic hypertrophy, the breast bud is neither red nor tender. The nipple discharge (if present) in physiologic hypertrophy is milky rather than purulent and does not contain polymorphonuclear white blood cells or bacteria on Gram stain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42776?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of breast masses in children and adolescents\", section on 'Neonates and infants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conditions that can mimic mastitis in",
"    <span class=\"nowrap\">",
"     pubertal/postpubertal",
"    </span>",
"    girls include mammary duct ectasia, recurrent subareolar abscess, superficial thrombophlebitis of the thoracoepigastric vein (Mondor's disease), trauma, and carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42776?source=see_link\">",
"     \"Overview of breast masses in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Mastitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of mastitis varies with age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     In neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized controlled studies have evaluated antibiotic regimens for neonatal mastitis. Recommendations for treatment are based upon the causative pathogens and the response to therapy described in observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/2,22\">",
"     2,22",
"    </a>",
"    ]. Because of the potential for breast abscess, neonates should be treated with parenteral antibiotics guided by Gram stain when available [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One small series noted that all five patients who were treated with oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    before presentation developed breast abscesses (even though the cultured organism was susceptible to amoxicillin-clavulanate) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/2\">",
"     2",
"    </a>",
"    ]. This observation supports the use of parenteral therapy in this young patient population.",
"   </p>",
"   <p>",
"    We recommend that neonatal mastitis be treated initially with parenteral antibiotics if the infant is febrile, ill appearing, has leukocytosis, or is younger than 28 days of age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/2,3,20,22\">",
"     2,3,20,22",
"    </a>",
"    ]. We also suggest initial parenteral antibiotics for infants who are afebrile, well appearing, without leukocytosis, and older than 28 days of age, given the potential for progression to abscess in infants who are initially treated orally and the increasing prevalence of community-associated methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (CA-MRSA) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/2,22\">",
"     2,22",
"    </a>",
"    ]. The empiric antibiotic choice should be guided by local susceptibility patterns and the Gram stain, if one is available [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/2,3,20,22,28\">",
"     2,3,20,22,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If gram-positive cocci are identified, empiric therapy should include coverage for",
"      <em>",
"       S. aureus",
"      </em>",
"      . In communities where CA-MRSA infections are rare, a penicillinase-resistant antibiotic (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/59/950?source=see_link\">",
"       oxacillin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/57/26519?source=see_link\">",
"       nafcillin",
"      </a>",
"      ) may be used. In areas with an increased incidence of CA-MRSA (more than 10 percent of community isolates),",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      is appropriate [",
"      <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=see_link&amp;anchor=H24#H24\">",
"       \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Treatment of neonates'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If gram-negative organisms are identified, empiric therapy should include an aminoglycoside (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"       amikacin",
"      </a>",
"      ) or third-generation cephalosporin (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If the Gram stain is not available or if no organisms are seen, we suggest that empiric therapy include coverage for",
"      <em>",
"       S. aureus",
"      </em>",
"      and gram-negative enteric organisms [",
"      <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/4,14,22\">",
"       4,14,22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For neonates with severe complications due to mastitis, including extensive cellulitis, necrotizing fasciitis, osteomyelitis, and shock, we recommend parenteral antimicrobial therapy with broad empiric coverage for MRSA, methicillin-susceptible",
"    <em>",
"     S. aureus",
"    </em>",
"    , and gram-negative organisms (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/57/26519?source=see_link\">",
"     nafcillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapy can be altered according to culture results once they are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17018?source=see_link&amp;anchor=H17#H17\">",
"     \"Approach to the septic-appearing infant\", section on 'Antibiotics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Treatment of neonates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Incision and drainage may be warranted if an abscess is present. If incision and drainage are performed, it is important not to injure the underlying breast bud; appropriately trained personnel (eg, a breast surgeon or pediatric gynecologist) should be consulted when this procedure is necessary.",
"   </p>",
"   <p>",
"    The duration of therapy depends upon the clinical response; a total of 7 to 14 days (parenteral and oral) is usually adequate if there are no complications [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/2,3,22\">",
"     2,3,22",
"    </a>",
"    ]. Patients without complications may be transitioned from parenteral to oral therapy if the following criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Resolution of systemic symptoms and fever",
"     </li>",
"     <li>",
"      Improvement in other clinical findings",
"     </li>",
"     <li>",
"      Antibiotic susceptibility results are available",
"     </li>",
"     <li>",
"      Systemic bacterial cultures (urine, blood, CSF) isolate no pathogens after 48 hours of incubation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend close follow-up by phone and office visits for all neonatal patients receiving oral antibiotics to assess for medication adherence and treatment failure (a possible indication of the need for abscess drainage) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/9,22\">",
"     9,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     In children and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized controlled trials have evaluated antibiotic regimens for mastitis in older children and adolescents. Recommendations for treatment are based upon the causative pathogens and response to therapy described in observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/1,10\">",
"     1,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest oral antimicrobial therapy for older children and adolescents with mastitis who are well appearing and without systemic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/13\">",
"     13",
"    </a>",
"    ]. Those with systemic symptoms should be treated parenterally.",
"   </p>",
"   <p>",
"    The choice of antibiotics should be guided by the Gram stain if one is available and a pathogenic organism is identified. If a Gram stain is not available, empiric therapy should include coverage for",
"    <em>",
"     Staphylococcus",
"    </em>",
"    (including CA-MRSA) and",
"    <em>",
"     Streptococcus",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2005 Infectious Diseases Society of America (IDSA) guidelines on the diagnosis and management of skin and soft-tissue infections recommend therapy with a penicillinase-resistant semisynthetic penicillin or a first-generation cephalosporin for cellulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/30\">",
"     30",
"    </a>",
"    ]. Patients are treated for 7 to 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Appropriate oral drugs include",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/61/17363?source=see_link\">",
"       dicloxacillin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/45/31446?source=see_link\">",
"       cloxacillin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/5/30804?source=see_link\">",
"       cephalexin",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      unless streptococci or staphylococci resistant to these drugs are common in the community [",
"      <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/30\">",
"       30",
"      </a>",
"      ]. Clindamycin or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      may be necessary in areas with increased incidence of CA-MRSA (more than 10 percent of community isolates). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=see_link&amp;anchor=H10#H10\">",
"       \"Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children\", section on 'Approach for children &gt;30 days of age'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If parenteral therapy is warranted,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/57/26519?source=see_link\">",
"       nafcillin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/59/950?source=see_link\">",
"       oxacillin",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/36/9797?source=see_link\">",
"       cefazolin",
"      </a>",
"      are acceptable if CA-MRSA is not a concern [",
"      <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/30\">",
"       30",
"      </a>",
"      ].",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      can be used for patients in whom CA-MRSA is a concern and in those with life-threatening penicillin allergy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=see_link&amp;anchor=H14#H14\">",
"       \"Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children\", section on 'Severe SSTI'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"       \"Allergy to penicillins\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=see_link\">",
"       \"Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care may include the application of warm compresses and provision of breast support [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with mastitis have clinical improvement within 24 to 48 hours of appropriate antibiotic therapy. If symptoms progress or fail to improve, options include a change in the antimicrobial regimen (eg, to include activity against less frequent pathogens or parenteral therapy) and, if abscess is present, aspiration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    incision and drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/6,14,22,32\">",
"     6,14,22,32",
"    </a>",
"    ]. Drainage of an abscess can be performed with ultrasound guidance if deemed necessary. Ultrasound may be helpful to diagnose abscess when induration makes detection of fluctuance difficult to assess [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrent infection or persistence of a mass after treatment for infection may also signal breast abscess formation or an underlying lesion such as a hemangioma, lymphangioma, or cystic hygroma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Breast abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to antibiotic therapy, breast abscess (in both neonates and older children) may require aspiration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    incision and drainage unless spontaneous drainage occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/2,3,6,32\">",
"     2,3,6,32",
"    </a>",
"    ]. Neonates frequently require a drainage procedure. During aspiration, care must be taken to avoid the breast bud [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/5,13,32\">",
"     5,13,32",
"    </a>",
"    ]. If incision and drainage are necessary, they should be performed by appropriately trained personnel (eg, a breast surgeon or pediatric gynecologist) because of the potential for breast hypoplasia or scarring after this procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/37/3673?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of breast disorders in children and adolescents\", section on 'Breast asymmetry'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data regarding the long-term outcome of mastitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/2\">",
"     2",
"    </a>",
"    ]. Most patients have an excellent prognosis, but there are case reports of breast asymmetry following incision and drainage for breast abscess during infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/1,4,34\">",
"     1,4,34",
"    </a>",
"    ]. Recurrences are rare, but patients should be followed closely [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with",
"    <em>",
"     S. aureus",
"    </em>",
"    mastitis are at risk for subsequent",
"    <em>",
"     S. aureus",
"    </em>",
"    infections at other sites [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4680/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breast infection usually occurs in infants younger than two months of age and lactating women, but also can occur in children and nonlactating adolescents. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and predisposing factors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=see_link\">",
"       \"Common problems of breastfeeding and weaning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In neonates, breast hypertrophy from maternal hormones and maternal skin or soft-tissue infection in the postpartum period predisposes breast infection. In",
"      <span class=\"nowrap\">",
"       pubertal/postpubertal",
"      </span>",
"      adolescents, predisposing factors include trauma, obesity, mammary duct ectasia, local skin infection, and epidermoid cysts. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and predisposing factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      is the most frequent cause of breast infection in neonates, children, and adolescents. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A clinical diagnosis of mastitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      breast abscess can be made in patients with swelling, erythema, warmth, tenderness, induration,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fluctuance of the breast. Gram stain and cultures confirm the diagnosis and direct antimicrobial therapy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In neonates, a complete blood count and blood culture should be obtained before the initiation of antimicrobial therapy. Urine and cerebrospinal fluid cultures should be obtained if these studies are clinically indicated (eg, if the infant is febrile, ill appearing, younger than 28 days of age, or has leukocytosis). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28074?source=see_link\">",
"       \"Evaluation and management of fever in the neonate and young infant (less than three months of age)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17018?source=see_link\">",
"       \"Approach to the septic-appearing infant\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend that neonatal mastitis be treated initially with parenteral antibiotics if the infant is febrile, ill appearing, has leukocytosis, or is younger than 28 days of age (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We also suggest initial parenteral antibiotics for infants who are afebrile, well appearing, without leukocytosis, and older than 28 days of age, given the potential for progression to abscess in infants who are initially treated orally and the increasing prevalence of community-associated methicillin-resistant",
"      <em>",
"       S. aureus",
"      </em>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Initial therapy is based upon the Gram stain (if available) and local susceptibility patterns. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'In neonates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that mastitis in older children and adolescents who are well appearing and without systemic symptoms be treated with oral antibiotics (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Initial therapy is based upon the Gram stain if one is available and informative. If Gram stain is not available, empiric therapy should include coverage for",
"      <em>",
"       Staphylococcus",
"      </em>",
"      and",
"      <em>",
"       Streptococcus",
"      </em>",
"      . Appropriate drugs include",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/61/17363?source=see_link\">",
"       dicloxacillin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/45/31446?source=see_link\">",
"       cloxacillin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/5/30804?source=see_link\">",
"       cephalexin",
"      </a>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      ; clindamycin or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      may be necessary in areas with increased incidence of CA-MRSA. Treatment is usually continued for 7 to 10 days. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'In children and adolescents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to antibiotic therapy, breast abscess may require aspiration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      incision and drainage unless spontaneous drainage occurs. Neonates frequently require drainage. Drainage under ultrasound guidance is an option. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Breast abscess'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients have an excellent prognosis. However, there are case reports of breast asymmetry following incision and drainage for breast abscess during infancy. Recurrences are rare. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/1\">",
"      Faden H. Mastitis in children from birth to 17 years. Pediatr Infect Dis J 2005; 24:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/2\">",
"      Stricker T, Navratil F, Sennhauser FH. Mastitis in early infancy. Acta Paediatr 2005; 94:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/3\">",
"      Walsh M, McIntosh K. Neonatal mastitis. Clin Pediatr (Phila) 1986; 25:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/4\">",
"      Rudoy RC, Nelson JD. Breast abscess during the neonatal period. A review. Am J Dis Child 1975; 129:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/5\">",
"      Efrat M, Mogilner JG, Iujtman M, et al. Neonatal mastitis--diagnosis and treatment. Isr J Med Sci 1995; 31:558.",
"     </a>",
"    </li>",
"    <li>",
"     DiVasta AD, Weldon C, Labow BI. The breast: Examination and lesions. In: Emans, Laufer, Goldstein's Pediatric &amp; Adolescent Gynecology, 6th, Emans SJ, Laufer MR.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. p.405.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/7\">",
"      Rench MA, Baker CJ. Group B streptococcal breast abscess in a mother and mastitis in her infant. Obstet Gynecol 1989; 73:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/8\">",
"      Fortunov RM, Hulten KG, Hammerman WA, et al. Community-acquired Staphylococcus aureus infections in term and near-term previously healthy neonates. Pediatrics 2006; 118:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/9\">",
"      Montalto M, Lui B. MRSA as a cause of postpartum breast abscess in infant and mother. J Hum Lact 2009; 25:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/10\">",
"      Stricker T, Navratil F, Forster I, et al. Nonpuerperal mastitis in adolescents. J Pediatr 2006; 148:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/11\">",
"      Greydanus DE, Matytsina L, Gains M. Breast disorders in children and adolescents. Prim Care 2006; 33:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/12\">",
"      Templeman C, Hertweck SP. Breast disorders in the pediatric and adolescent patient. Obstet Gynecol Clin North Am 2000; 27:19.",
"     </a>",
"    </li>",
"    <li>",
"     Baren JM. Breast lesions. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams and Wilkins, Philadelphia 2006. p.193.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/14\">",
"      Brook I. The aerobic and anaerobic microbiology of neonatal breast abscess. Pediatr Infect Dis J 1991; 10:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/15\">",
"      Stetler H, Martin E, Plotkin S, Katz M. Neonatal mastitis due to Escherichia coli. J Pediatr 1970; 76:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/16\">",
"      Burry VF, Beezley M. Infant mastitis due to gram-negative organisms. Am J Dis Child 1972; 124:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/17\">",
"      Schwarz MD, Rosen RA. Neonatal mastitis due to E. coli. Clin Pediatr (Phila) 1974; 13:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/18\">",
"      McGuigan MA, Lipman RP. Neotal mastitis due to Proteus mirabilis. Am J Dis Child 1976; 130:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/19\">",
"      Sloan B, Evans R. Clinical pearls: neonatal breast mass. Acad Emerg Med 2003; 10:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/20\">",
"      Stauffer WM, Kamat D. Neonatal mastitis. Pediatr Emerg Care 2003; 19:165.",
"     </a>",
"    </li>",
"    <li>",
"     Fortunov R, Mednax/Pediatrix Medical Group, 2009, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/22\">",
"      Fortunov RM, Hulten KG, Hammerman WA, et al. Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates. Pediatrics 2007; 120:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/23\">",
"      Hsieh WS, Yang PH, Chao HC, Lai JY. Neonatal necrotizing fasciitis: a report of three cases and review of the literature. Pediatrics 1999; 103:e53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/24\">",
"      Nelson JD. Suppurative mastitis in infants. Am J Dis Child 1973; 125:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/25\">",
"      Michael, IK, Howard, FH. Osteomyelitis due to penicillin-resistant staphylococci in infancy following suppurative mastitis. (Report of a case). J Trop Pediatr 1960; 6:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/26\">",
"      Bodemer C, Panhans A, Chretien-Marquet B, et al. Staphylococcal necrotizing fasciitis in the mammary region in childhood: a report of five cases. J Pediatr 1997; 131:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/27\">",
"      Perl B, Gottehrer NP, Raveh D, et al. Cost-effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis 1999; 29:1483.",
"     </a>",
"    </li>",
"    <li>",
"     Fleisher, GR. Infectious disease emergencies. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM (Eds), Liippincott Williams &amp; Wilkins, Philadelphia 2006. p.783.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/29\">",
"      Schwartz GF. Benign neoplasms and \"inflammations\" of the breast. Clin Obstet Gynecol 1982; 25:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/30\">",
"      Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/31\">",
"      Ladhani S, Garbash M. Staphylococcal skin infections in children: rational drug therapy recommendations. Paediatr Drugs 2005; 7:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/32\">",
"      Schwarz RJ, Shrestha R. Needle aspiration of breast abscesses. Am J Surg 2001; 182:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/33\">",
"      Borders H, Mychaliska G, Gebarski KS. Sonographic features of neonatal mastitis and breast abscess. Pediatr Radiol 2009; 39:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4680/abstract/34\">",
"      Panteli C, Arvaniti M, Zavitsanakis A. Long-term consequences of neonatal mastitis. Arch Dis Child 2012; 97:673.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5974 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-853D91569B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_36_4680=[""].join("\n");
var outline_f4_36_4680=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND PREDISPOSING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neonatal mastitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      In nonlactational mastitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Nonlactational mastitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Lactational mastitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Of neonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Of nonlactational mastitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Mastitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - In neonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - In children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Supportive care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Response to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Breast abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17018?source=related_link\">",
"      Approach to the septic-appearing infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9495?source=related_link\">",
"      Breast abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=related_link\">",
"      Common problems of breastfeeding and weaning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28074?source=related_link\">",
"      Evaluation and management of fever in the neonate and young infant (less than three months of age)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=related_link\">",
"      Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/28/454?source=related_link\">",
"      Lactational mastitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/37/3673?source=related_link\">",
"      Overview of breast disorders in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42776?source=related_link\">",
"      Overview of breast masses in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=related_link\">",
"      Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_36_4681="Cutaneous lichen planus histopathology";
var content_f4_36_4681=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cutaneous lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This specimen from a lesion of cutaneous lichen planus demonstrates a band-like lymphocytic infiltrate, saw-tooth rete ridges, multiple apoptotic keratinocytes, and wedge-shaped hypergranulosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_36_4681=[""].join("\n");
var outline_f4_36_4681=null;
var title_f4_36_4682="Clinical use of coagulation tests";
var content_f4_36_4682=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical use of coagulation tests",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/36/4682/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/36/4682/contributors\">",
"     James L Zehnder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/36/4682/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/36/4682/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/36/4682/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/36/4682/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/36/4682/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine tests of blood coagulation, such as the prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin time (TT) are frequently ordered to assess clotting function in patients.",
"   </p>",
"   <p>",
"    The nature of these three tests and the evaluation of abnormal test results will be reviewed here. These tests are sensitive for a deficiency in one or more of the known procoagulants, but not whether the deficiency is counterbalanced by a parallel deficiency of anti-coagulants (eg, proteins C and S), which might be relevant in the evaluation of acquired coagulation defects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of these tests to manage anticoagulation is discussed briefly here, but is also presented separately, as are overviews of the coagulation pathway and the approach to the patient with a bleeding disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"     \"Approach to the adult patient with a bleeding diathesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link\">",
"     \"Approach to the child with bleeding symptoms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OBTAINING THE SAMPLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A properly drawn blood sample is the key to interpreting the results of clotting tests. The following are guidelines for obtaining the best possible sample:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Whole blood is collected into citrated anticoagulant, using an evacuated sample tube containing a fixed amount of citrate as anticoagulant, in the ratio of one part citrate solution to nine parts of whole blood. If the patient is polycythemic (ie, hematocrit &gt;55 percent), the amount of plasma in the removed sample will be reduced compared with the amount of plasma present in the same volume of whole blood in a patient with a normal hematocrit. As a result, the volume of citrated anticoagulant solution needs to be decreased proportionately for patients with high hematocrits. If these guidelines are not followed, clotting times may be artifactually prolonged due to overanticoagulation of the sample [",
"      <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If the pediatric sample tube (volume 2.7 mL) is not filled to within 90 percent of its full collection volume, or an adult sample tube (volume 5 mL) is not filled to at least 60 to 80 percent of its full collection volume, there will be excessive anticoagulation of the sample, leading to prolonged clotting times [",
"      <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. Accordingly, incompletely filled sample tubes should be discarded and the sample redrawn.",
"     </li>",
"     <li>",
"      The sample must be free of tissue fluids, intravenous solutions delivered through indwelling lines, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      . This is especially important for blood samples obtained from central venous catheters, such as those used for hemodialysis or administration of chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/5-8\">",
"       5-8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For sampling from indwelling lines and for difficult-to-obtain samples, especially those obtained by inexperienced personnel, a",
"      <strong>",
"       two-syringe technique",
"      </strong>",
"      is often used. The first few mL drawn into the first syringe (or evacuated tube) are discarded and the required sample is obtained from the second syringe or tube.",
"     </li>",
"     <li>",
"      The anticoagulated blood should be mixed gently by inversion three or four times, sent to the laboratory in an expeditious manner, and tested within two hours if kept at room temperature (22 to 24&deg;C) or within four hours if kept cold (2 to 4&deg;C).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For some situations, the two-syringe technique is unnecessary [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. As an example, blood was drawn by experienced phlebotomists in a series of 175 outpatients, using a two-syringe technique [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/9\">",
"     9",
"    </a>",
"    ]. The mean differences between tubes one and two for the prothrombin time (PT) and activated partial thromboplastin time (aPTT) were 0.1 and 0.48 seconds, respectively (p values &gt;0.8 for both). Similar conclusions were reached for determination of INR (see below) in a study of 241 outpatients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ; the differences between tubes one and two were either statistically or clinically insignificant [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is helpful for the laboratory to know if the patient is taking a medication (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ) which may affect one or more of the coagulation tests, as well as whether the test is being ordered to monitor such therapy, or has been obtained for diagnostic reasons. This information may affect the type of testing performed. Thus, if the patient is known to be taking warfarin and a prothrombin time is ordered, the laboratory may only measure the INR (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Measurement of INR'",
"    </a>",
"    below). If, on the other hand, the patient is not taking warfarin and the prothrombin time is prolonged, the laboratory may do additional testing, such as a mixing test to determine whether the prolongation is due to a factor deficiency or the presence of an inhibitor (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Mixing studies'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Normal values",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the tests mentioned below have endpoints measured in seconds. The exception is the \"INR\", which is dimensionless, since it is a ratio. For all of the tests described here, the normal ranges generally vary from one laboratory to another. Again, the exception is the INR, which takes sources of test variability (eg, reagents, laboratory equipment) into account (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Measurement of INR'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Normal values for each of the tests listed below (with the exception of the INR) are obtained by testing at least 30 normal, non-pregnant subjects using the same methodology as employed for the patient samples. The normal range (mean &plusmn; 2 standard deviations) for the testing laboratory should be stated whenever the laboratory reports its results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PROTHROMBIN TIME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prothrombin time (PT) (",
"    <a class=\"graphic graphic_figure graphicRef79998 \" href=\"UTD.htm?23/62/24558\">",
"     figure 1",
"    </a>",
"    ) is used to assess the extrinsic pathway of clotting, which consists of tissue factor and factor VII, and coagulation factors in the common pathway (factors II [prothrombin], V, X, and fibrinogen). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In this test, clotting is initiated by recalcifying citrated patient plasma in the presence of thromboplastin (tissue factor). The endpoint for the PT (and also for the partial thromboplastin and thrombin times) is the time (in seconds) for the formation of a fibrin clot, which is detected by visual, optical, or electromechanical means. The sensitivity of the PT to reduced activity of the vitamin K-dependent factors within this pathway (ie, factors VII, X, and II; especially factor VII) comprises the rationale for the use of the PT to monitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Monitoring warfarin therapy'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Results of the prothrombin time can be expressed in one of four different ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       PT with control value",
"      </strong>",
"      &mdash; The patient&rsquo;s PT (in seconds) is reported along with the PT obtained from control (normal) plasma. The control value is needed since there can be significant inter-laboratory variability in the PT with different",
"      <span class=\"nowrap\">",
"       reagent/instrument",
"      </span>",
"      combinations.",
"     </li>",
"     <li>",
"      <strong>",
"       PT expressed as INR",
"      </strong>",
"      &mdash; In order to promote standardization of the PT for monitoring oral anticoagulant therapy, the World Health Organization (WHO) developed an international reference thromboplastin, currently recombinant tissue factor, and recommended that the PT ratio be expressed as the International Normalized Ratio or INR [",
"      <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/11\">",
"       11",
"      </a>",
"      ]. This allows values of the PT from various locations to be directly compared, as may happen when a patient taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      has blood sampled at different laboratories. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Measurement of INR'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Prothrombin time ratio (PTr)",
"      </strong>",
"      &mdash; The patient&rsquo;s PT is expressed as a ratio, where PTr = (patient PT &divide; control PT). As an example, a PTr &gt;1.2 was associated with a significantly increased risk of acute traumatic coagulopathy in a large multicenter retrospective study [",
"      <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/12\">",
"       12",
"      </a>",
"      ]. In this study, reagents used had similar sensitivities (ISI range 1.03-1.09). A limitation of this method is that",
"      <span class=\"nowrap\">",
"       reagent/instrument",
"      </span>",
"      variability may affect the results.",
"     </li>",
"     <li>",
"      <strong>",
"       Prothrombin time index (PTI)",
"      </strong>",
"      &mdash; The PTI is defined as PTI = (control",
"      <span class=\"nowrap\">",
"       PT)/(Patient",
"      </span>",
"      PT) x 100. As the calculation is essentially the inverse of the PTr, the same limitations apply.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the United States, most laboratories report the PT in seconds and also as the INR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Causes of prolonged PT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , there are other causes of prothrombin time prolongation. These include (",
"    <a class=\"graphic graphic_table graphicRef79969 \" href=\"UTD.htm?42/45/43740\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vitamin K deficiency due, for example, to poor nutrition, or prolonged use of broad spectrum antibiotics. When vitamin K deficiency is mild, only the PT may be prolonged, due to a predominant effect on factor VII. However, in severe vitamin K deficiency, both the PT and aPTT may be prolonged. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of vitamin K\", section on 'Deficiency'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26663?source=see_link&amp;anchor=H18#H18\">",
"       \"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects\", section on 'Hematologic reactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Liver disease, which decreases the synthesis of both vitamin K-dependent and -independent clotting factors. When liver disease is mild, only the PT may be prolonged, due to a predominant effect on factor VII. However, in severe",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chronic liver disease, both the PT and aPTT may be prolonged. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24022?source=see_link\">",
"       \"Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=see_link&amp;anchor=H166750581#H166750581\">",
"       \"Acute liver failure in adults: Management and prognosis\", section on 'Bleeding prevention'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Deficiency or inhibition of factors VII [",
"      <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/13\">",
"       13",
"      </a>",
"      ], X, II (prothrombin), V, or fibrinogen (",
"      <a class=\"graphic graphic_figure graphicRef79998 \" href=\"UTD.htm?23/62/24558\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The infrequent antiphospholipid antibodies (lupus anticoagulant phenomenon) with antiprothrombin activity. In such patients, the acquired prothrombin deficiency may be severe enough to cause clinical bleeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link\">",
"       \"Pathogenesis of the antiphospholipid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      While treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      does not normally prolong the PT (due to the addition of heparin-neutralizing materials to the PT reagent), the PT may be transiently elevated after bolus administration of heparin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Monitoring warfarin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anticoagulant effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is mediated by inhibition of the vitamin K-dependent gamma-carboxylation of coagulation factors II, VII, IX, and X [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/14\">",
"     14",
"    </a>",
"    ]. This results in the synthesis of immunologically detectable but biologically inactive forms of these coagulation proteins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/32/20999?source=see_link\">",
"     \"Vitamin K, gamma carboxyglutamic acid, and the function of coagulation and other proteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The full anticoagulant effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is delayed until the normal clotting factors are cleared from the circulation, and the peak effect does not occur until 36 to 72 hours after drug administration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/15\">",
"     15",
"    </a>",
"    ]. During the first few days of warfarin therapy, prolongation of the PT mainly reflects depression of factor VII, which has a half-life of only five to seven hours; thus, the intrinsic coagulation pathway that does not require factor VII remains intact (",
"    <a class=\"graphic graphic_figure graphicRef50940 \" href=\"UTD.htm?26/56/27534\">",
"     figure 2",
"    </a>",
"    ). Equilibrium levels of factors II, IX, and X are not reached until about one week after the initiation of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H6#H6\">",
"     \"Therapeutic use of warfarin\", section on 'Mechanism of action'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Measurement of INR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The INR, which compensates for differences in sensitivity of various PT reagents to the effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , is used to monitor warfarin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/11\">",
"     11",
"    </a>",
"    ]. The INR is calculated from the following formula:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp;INR &nbsp;= &nbsp;[Patient PT &divide; Control PT]",
"    <sup>",
"     ISI",
"    </sup>",
"   </p>",
"   <p>",
"    The ISI (international sensitivity index) should be determined for each PT reagent and instrument combination. Although the ISI is traceable to an international reference thromboplastin reagent, it is useful to have the ISI value confirmed within each laboratory, since this may be affected by differences in handling of the reagents and the type of equipment used [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The control value for the PT is the mean normal prothrombin time for the laboratory, and should be determined from &ge;20 fresh normal plasmas handled identically to patient material. Apparatus that allows the patient to monitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy at home is now available (",
"    <a class=\"graphic graphic_figure graphicRef52321 \" href=\"UTD.htm?31/42/32429\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35880?source=see_link\">",
"     \"Outpatient management of oral anticoagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , the therapeutic range for the INR varies with the clinical indication. For most indications the recommended range is 2.0 to 3.0 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/14\">",
"     14",
"    </a>",
"    ]. A higher (or lower) INR range may be recommended in certain specific clinical settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H23#H23\">",
"     \"Therapeutic use of warfarin\", section on 'Initial dose'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H24#H24\">",
"     \"Therapeutic use of warfarin\", section on 'Maintenance therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of the antiphospholipid syndrome\", section on 'Specific clinical settings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H26#H26\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Idiopathic VTE'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Appropriate treatment of a patient with an INR that is prolonged beyond the therapeutic range (ie, a prolonged or excessive INR) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link\">",
"     \"Correcting excess anticoagulation after warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     The INR in liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The INR was specifically devised for monitoring patients undergoing treatment with vitamin K antagonists. Accordingly, the INR may not be directly applicable to patients with liver disease, whose pattern of changes in both vitamin K-dependent and vitamin K-independent procoagulant and anticoagulant factors are dissimilar [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/17\">",
"     17",
"    </a>",
"    ]. This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24022?source=see_link&amp;anchor=H7#H7\">",
"     \"Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)\", section on 'International normalized ratio'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link&amp;anchor=H5858423#H5858423\">",
"     \"Coagulation abnormalities in patients with liver disease\", section on 'Prothrombin time (PT) and the International Normalized Ratio (INR)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Monitoring warfarin therapy in the antiphospholipid syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports have challenged the reproducibility and validity of the PT(INR) for monitoring patients with lupus anticoagulants who are taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. If this is a problem, alternative methods of monitoring warfarin effect which are insensitive to the presence of a lupus anticoagulant are required. There are a number of possible solutions to this problem:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use of a chromogenic factor Xa assay",
"     </li>",
"     <li>",
"      Use of the prothrombin-proconvertin time instead of the INR (not available in the United States)",
"     </li>",
"     <li>",
"      Use of a commercial reagent insensitive to the patient's particular antiphospholipid antibody.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This problem is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=see_link&amp;anchor=H32#H32\">",
"     \"Treatment of the antiphospholipid syndrome\", section on 'Problems in monitoring INR'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ACTIVATED PARTIAL THROMBOPLASTIN TIME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The activated partial thromboplastin time (aPTT or PTT) (",
"    <a class=\"graphic graphic_figure graphicRef79998 \" href=\"UTD.htm?23/62/24558\">",
"     figure 1",
"    </a>",
"    ) is used to assess the integrity of the intrinsic coagulation pathway (prekallikrein, high molecular weight kininogen, factors XII, XI, IX, VIII) and final common pathway (factors II, V, X, and fibrinogen), and to monitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The test is performed by recalcifying citrated plasma in the presence of a thromboplastic material that does not have tissue factor activity (hence the term partial thromboplastin) and a negatively charged substance (eg, celite, kaolin, silica), which results in contact factor activation, thereby initiating coagulation via the intrinsic clotting pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Causes of prolonged aPTT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolongation of the aPTT can occur with a deficiency of, or an inhibitor to, any of the clotting factors except for factor VII (",
"    <a class=\"graphic graphic_figure graphicRef79998 \" href=\"UTD.htm?23/62/24558\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef79969 \" href=\"UTD.htm?42/45/43740\">",
"     table 1",
"    </a>",
"    ). In addition, certain lupus anticoagulants, which are antibodies directed against plasma proteins bound to anionic phospholipids, cause aPTT prolongation by interfering with the in vitro assembly of the prothrombinase complex. This in vitro event is paradoxically associated with an increased risk of venous and arterial thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At present, aPTT methods are not standardized in a manner analogous to that used to determine the INR from the prothrombin time (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Measurement of INR'",
"    </a>",
"    above). As a result, different reagent and instrument combinations result in variations in test results [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/21\">",
"     21",
"    </a>",
"    ]. Of importance, some commercial reagents have reduced sensitivity to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and may not be suitable for monitoring the effect of heparin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Monitoring heparin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    is an indirect thrombin inhibitor which complexes with antithrombin (AT), converting this circulating cofactor from a slow to a rapid inactivator of thrombin, factor Xa, and to a lesser extent, factors XIIa, XIa, and IXa. In patients with venous thromboembolism, adequate heparin anticoagulation must be achieved within the first 24 hours to reduce the risk of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Unfractionated heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The critical therapeutic level of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    to be reached within 24 hours (as measured by the aPTT) is 1.5 times the mean of the control value or the upper limit of the normal aPTT range. The goal of maintenance heparin therapy is to maintain the aPTT in the range of",
"    <strong>",
"     1.5 to 2.5 times",
"    </strong>",
"    the patient's aPTT baseline value. This level of anticoagulation corresponds roughly to a heparin blood concentration of 0.2 to 0.4",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    by the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/9/11413?source=see_link\">",
"     protamine sulfate",
"    </a>",
"    titration assay, and 0.3 to 0.7",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    by the chromogenic anti-factor Xa heparin assay. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link&amp;anchor=H7#H7\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Heparin monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is, however, a wide variability in the aPTT and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    blood levels with different reagents and even with different batches of the same reagent. As a result, it is recommended for each laboratory to establish the minimal therapeutic level of heparin, as measured by the aPTT, that will provide a heparin blood level of at least 0.2",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    by the protamine titration assay for each batch of thromboplastin reagent being used; this is particularly important if the reagent is provided by a different manufacturer.",
"   </p>",
"   <p>",
"    As with unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , low molecular weight heparins (LMWHs) inactivate factor Xa, but have a lesser effect on thrombin because most of the molecules are not long enough to bind to thrombin and AT simultaneously. As a result, LMWHs often do not prolong the aPTT. However, laboratory monitoring is not necessary in nonpregnant patients because the anticoagulant response (anti-Xa activity) to a fixed dose of LMW heparin is highly correlated with the patient's body weight, and there is little correlation between anti-Xa activity and either bleeding or recurrent thrombosis. If necessary, monitoring can be performed by testing for anti-factor Xa activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link&amp;anchor=H7#H7\">",
"     \"Anticoagulation during pregnancy\", section on 'LMW heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     THROMBIN TIME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thrombin time (TT) measures the final step of the clotting pathway, the conversion of fibrinogen to fibrin. The test is performed by recalcifying citrated plasma in the presence of dilute bovine or human thrombin and recording the time (in seconds) for a clot to form [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Causes of prolonged TT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following conditions cause a prolongation of the TT [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , a direct thrombin inhibitor such as hirudin, hirulog, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20375?source=see_link\">",
"       argatroban",
"      </a>",
"      , or heparan-like compounds (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/18/41254?source=see_link\">",
"       danaparoid",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link&amp;anchor=H7#H7\">",
"       \"Anticoagulants other than heparin and warfarin\", section on 'Direct thrombin inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of",
"      <span class=\"nowrap\">",
"       fibrin/fibrinogen",
"      </span>",
"      degradation products",
"     </li>",
"     <li>",
"      Hypofibrinogenemia (&lt;100",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      dysfibrinogenemia, or hyperfibrinogenemia (&gt;400",
"      <span class=\"nowrap\">",
"       mg/dL).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=see_link\">",
"       \"Disorders of fibrinogen\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bovine thrombin antibodies from prior exposure to bovine thrombin (only when tested using bovine thrombin reagent; TT will be normal if tested using human thrombin reagent)",
"     </li>",
"     <li>",
"      High concentrations of serum proteins, as in multiple myeloma and amyloidosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who have been exposed to bovine thrombin during surgery may develop antibodies to bovine thrombin. In general, such antibodies are specific for bovine thrombin and are usually not associated with an increased bleeding risk unless they crossreact with human thrombin or the patient has coexisting inhibitors to other clotting factors.",
"   </p>",
"   <p>",
"    Occasional patients exposed to topical bovine thrombin develop antibodies to bovine factor V present in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40612?source=see_link\">",
"     topical thrombin",
"    </a>",
"    preparation, which crossreact with human factor V, causing prolongation of the PT and aPTT and a significant bleeding risk [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link&amp;anchor=H21#H21\">",
"     \"Acquired inhibitors of coagulation\", section on 'Thrombin inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Reptilase time",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reptilase is an enzyme similar to thrombin that is found in the venom of Bothrops snakes. However, it differs from thrombin by generating fibrinopeptide A but not fibrinopeptide B from fibrinogen and by resisting inhibition by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    via antithrombin.",
"   </p>",
"   <p>",
"    The reptilase time (RT) is similar to the TT in measuring the conversion of fibrinogen to fibrin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/27\">",
"     27",
"    </a>",
"    ]. The reptilase time is useful for detecting abnormalities in fibrinogen (in which case the TT is also prolonged) and in detecting the presence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (heparin will cause prolongation of the TT but not reptilase time). Thus, the RT is most useful for determining if heparin is the cause of a prolonged TT (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Heparin in the sample'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Thrombin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct thrombin inhibitors such as hirudin, hirulog, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    are associated with prolongation of the PT, aPTT, and TT, but will not prolong the reptilase time. Argatroban, and probably the other direct thrombin inhibitors, can be effectively monitored with use of the aPTT or activated clotting times, but it interferes with the INR and aPTT for monitoring concomitant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy, respectively, as well as routine clot-based assays for fibrinogen and protein C [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/28\">",
"     28",
"    </a>",
"    ]. Specialized tests are available for monitoring such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link\">",
"     \"Anticoagulants other than heparin and warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ANTI FACTOR Xa ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti factor Xa activity can be measured in order to determine adequacy of anticoagulation in patients receiving agents that directly or indirectly interfere with factor Xa activity (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , low molecular weight (LMW) heparins, direct factor Xa inhibitors). The test is performed by adding patient plasma to an excess of factor Xa and antithrombin. The residual activity of factor Xa is proportional to the amount of the heparin or other factor Xa inhibitor in the plasma. This activity is measured using an artificial factor Xa substrate that releases a colored compound when cleaved (ie, chromogenic assay) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of anti-factor Xa activity to monitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and LMW heparin therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link&amp;anchor=H7#H7\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Heparin monitoring'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ACTIVATED WHOLE BLOOD CLOTTING TIME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The activated whole blood clotting time (ACT) is performed by addition of an activating agent (eg, celite, kaolin) to a sample of freshly-drawn whole blood and measuring the time (in seconds) for formation of a clot. This test has been generally replaced by the activated partial thromboplastin time (aPTT) for the clinical evaluation of coagulation defects, as well as for monitoring",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Activated partial thromboplastin time'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    However, the aPTT often becomes infinitely prolonged when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    concentrations exceed 1.0",
"    <span class=\"nowrap\">",
"     U/mL,",
"    </span>",
"    as employed in coronary artery bypass surgery or percutaneous coronary artery interventions. For such procedures, heparin monitoring is usually performed via the ACT, since this test shows a graded response to heparin concentrations in the range of 1 to 5",
"    <span class=\"nowrap\">",
"     U/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/30\">",
"     30",
"    </a>",
"    ]. Point-of-care instruments are available for this purpose, and have been successfully employed in the operating room, cardiac catheterization laboratory, and dialysis suites [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38120?source=see_link&amp;anchor=H2#H2\">",
"     \"Hemodialysis anticoagulation\", section on 'Standard anticoagulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H19#H19\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ACT is insensitive to the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    pentasaccharide",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    , and may be less sensitive to some low molecular weight heparins such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/33\">",
"     33",
"    </a>",
"    ]. However, the test has been successfully used to monitor treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/34\">",
"     34",
"    </a>",
"    ]. As with the aPTT, test results vary with the system employed, and need to be rigorously standardized in order to prevent over- or under-anticoagulation with these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/31,33\">",
"     31,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     FIBRIN D-DIMER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasmin cleaves fibrin at multiple sites and releases fibrin degradation products (FDPs). One of the major FDPs is D-dimer, which consists of two D domains from adjacent fibrin monomers that have been crosslinked by activated factor XIII. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21450?source=see_link&amp;anchor=H10#H10\">",
"     \"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis\", section on 'Fibrin degradation products and fibrin D-dimer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since D-dimer is generated from cross-linked fibrin, but not from fibrinogen, an elevated plasma concentration of D-dimer indicates recent or ongoing intravascular blood coagulation. A listing of the various conditions that lead to an increased D-dimer level is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef60881 \" href=\"UTD.htm?6/49/6940\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1023926\">",
"    <span class=\"h1\">",
"     ECARIN CLOTTING TIME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ecarin clotting time (ECT) is a coagulation test that has been used to monitor treatment with direct thrombin inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/35\">",
"     35",
"    </a>",
"    ]. Ecarin is a metalloproteinase derived from the venom of the saw-scaled viper Echis carinatus, which activates prothrombin to meizothrombin, an intermediate step in the conversion of prothrombin to thrombin. Meizothrombin has markedly reduced fibrinogen clotting activity compared with thrombin, and is not susceptible to inhibition by antithrombin or the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -antithrombin complex (due to steric hindrance), but it can readily complex with direct thrombin inhibitors (DTIs; eg, hirudin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/45/4823?source=see_link\">",
"     lepirudin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    ). Accordingly, the ECT is prolonged with increasing amounts of these DTIs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link&amp;anchor=H7#H7\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Direct thrombin inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although it has been suggested that the ECT be used to assess drug levels in patient taking the new DTI",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    , this test is not currently available in most coagulation laboratories. The aPTT and TT can also be used to assess dabigatran effect and are much more widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     EVALUATION OF ABNORMAL CLOTTING TIMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above clotting tests are primarily used to evaluate a patient with a possible bleeding diathesis or for monitoring therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"     \"Approach to the adult patient with a bleeding diathesis\"",
"    </a>",
"    .) Prolonged values are abnormal in the untreated patient, while shortened values may be predictive of an increase in coagulability (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Shortened clotting times'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prolonged clotting times",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simultaneously drawn PT (INR) and aPTT are needed in order to properly evaluate the coagulation system (",
"    <a class=\"graphic graphic_table graphicRef79969 \" href=\"UTD.htm?42/45/43740\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the aPTT is prolonged and the PT (INR) is normal, the problem is localized to the intrinsic pathway. Although the aPTT is abnormal in deficiencies of factors XII, prekallikrein, or high molecular weight kininogen, these disorders are not associated with clinical bleeding. The most common inherited bleeding disorders giving this picture are von Willebrand disease and isolated deficiencies of factors VIII, IX, and XI, while common acquired causes of this pattern are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      therapy (see",
"      <a class=\"local\" href=\"#H25\">",
"       'Heparin in the sample'",
"      </a>",
"      below) and the lupus anticoagulant phenomenon caused by the presence of antiphospholipid antibodies (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Antiphospholipid antibodies'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      If the aPTT is normal and the PT (INR) is prolonged, the problem lies in the extrinsic pathway (factor VII). The most common acquired causes are the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , chronic liver disease, and vitamin K deficiency. An acquired inhibitor of factor VII and congenital factor VII deficiency are rare causes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link&amp;anchor=H26#H26\">",
"       \"Acquired inhibitors of coagulation\", section on 'Factor VII inhibitors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16730?source=see_link&amp;anchor=H21#H21\">",
"       \"Rare (recessively inherited) coagulation disorders\", section on 'Factor VII deficiency'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If both the aPTT and PT (INR) are prolonged, the problem is likely to be in the final common pathway. In this situation, the thrombin time (TT) can be used to assess the last step in the pathway, conversion of fibrinogen to fibrin. If the TT is normal, the problem resides in the common pathway, due to abnormalities in factors II (prothrombin), V, or X. Common acquired conditions giving a prolonged PT and aPTT and a normal TT are liver disease, disseminated intravascular coagulation, and overanticoagulation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      . Conditions that prolong the TT are noted above (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Causes of prolonged TT'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      If both the aPTT and the PT (INR) are normal in a patient with a bleeding diathesis, then thrombocytopenia, mild deficiency of von Willebrand factor, platelet dysfunction, vascular disorders, and, rarely, factor XIII deficiency or a disorder of the fibrinolytic system should be considered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link&amp;anchor=H23#H23\">",
"       \"Approach to the adult patient with a bleeding diathesis\", section on 'Normal PT and aPTT'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Shortened clotting times",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary utility of coagulation tests is to detect clotting factor deficiencies or inhibitors, which result in prolonged clotting times. Under most circumstances, shortening of clotting times (PT, aPTT, or TT) reflects poor sample collection or preparation techniques. However, clotting factors may be increased or activated in vivo, as in malignancy, disseminated intravascular coagulation, or following short-term exercise, resulting in shortening of clotting times, especially the aPTT [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A shortened clotting time that does not appear to reflect technical error has been associated with an increased risk of thrombosis, recurrent thrombosis, recurrent miscarriage, or bleeding, and may increase the risk of thrombosis associated with other common thrombotic risk factors (eg, factor V Leiden, obesity, increased levels of D-Dimer) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/41-48\">",
"     41-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Mixing studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;After an abnormality in a clotting test has been detected, it is important to differentiate between a clotting factor deficiency and an inhibitor (eg, an antibody or other interfering substance (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ) directed against the clotting factor). This is accomplished by performing a mixing study, in which the patient's plasma is mixed in a 1:1 ratio with normal pooled plasma, and the abnormal tests are repeated.",
"   </p>",
"   <p>",
"    There are three important principles underlying such mixing tests:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As a general rule, clotting tests will give normal values when 50 percent activity of the involved coagulation factors are present. Thus, if the clotting test returns to normal after a 1:1 dilution with normal pooled plasma, a factor deficiency was the cause of the abnormal test.",
"     </li>",
"     <li>",
"      Most agents that inhibit clotting factor activity (such as antibodies) will not be effectively diluted out after addition of an equal volume of normal pooled plasma. Thus, if the test remains abnormal after 1:1 dilution, an inhibitor was the cause of the abnormal test.",
"     </li>",
"     <li>",
"      Some inhibitors may give normal results when tested immediately after 1:1 dilution; incubation of the diluted sample for up to two hours at 37&ordm;C may resolve this issue. As an example, delayed reactivity is characteristic of factor VIII inhibitors [",
"      <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/49\">",
"       49",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link&amp;anchor=H2#H2\">",
"       \"Acquired inhibitors of coagulation\", section on 'Factor VIII inhibitors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the 1:1 dilution corrects the abnormal test, the deficient factor(s) can be determined by individual clotting factor assays. If the test is not corrected by dilution, the most common inhibiting factors are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      in the sample (see",
"      <a class=\"local\" href=\"#H25\">",
"       'Heparin in the sample'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Antiphospholipid antibodies; these are more commonly associated with a hypercoagulable state rather than bleeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link\">",
"       \"Pathogenesis of the antiphospholipid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inhibitors directed against factors VIII, IX, or X. These inhibitors can be associated with",
"      <strong>",
"       life-threatening bleeding",
"      </strong>",
"      and require urgent attention by a hematologist and the involved laboratory. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link\">",
"       \"Acquired inhibitors of coagulation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inhibitors of thrombin, such as fibrin or fibrinogen degradation products. These can be detected using a variety of assays (such as fibrin degradation products or D-dimer).",
"     </li>",
"     <li>",
"      Inhibitors to other factors. These are less common and are detected by individual factor assays. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link\">",
"       \"Acquired inhibitors of coagulation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Antiphospholipid antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of an antiphospholipid antibody (aPL) producing the lupus anticoagulant phenomenon is suggested by the presence of a prolonged aPTT which does not correct after 1:1 dilution with normal pooled plasma in a nonbleeding patient with or without a known rheumatologic disorder. Demonstrating that addition of phospholipid corrects the clotting time confirms the presence of the lupus anticoagulant phenomenon.",
"   </p>",
"   <p>",
"    Clotting tests can be made more sensitive to the presence of aPL by reducing the concentration of lipid material (dilute PT or PTT), increasing preincubation times, or activating coagulation factors in vitro with kaolin (kaolin plasma clotting time).",
"   </p>",
"   <p>",
"    The dilute Russell viper venom test employs a 1:1 mixture of patient and control plasma along with limiting quantities of thromboplastic material. In this way it is sensitive to the amount of phospholipid available for assembly of the prothrombinase complex, and thus for the presence of antiphospholipid antibodies.",
"   </p>",
"   <p>",
"    The dilute Russell's viper venom time (dRVVT) is particularly sensitive to the presence of anti-&szlig;2-glycoprotein I antibodies (which are most closely correlated with thrombotic events), while the kaolin plasma clotting time is more sensitive to antiprothrombin antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link\">",
"     \"Pathogenesis of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there is currently no standardized test for the lupus anticoagulant phenomenon, and no internationally accepted reference or control materials. Furthermore, the test chosen, the source of the reagents, and instruments used in the assay all affect the ability to detect a lupus anticoagulant [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of an aPL is confirmed by demonstrating correction of the clotting time by added phospholipid. This can be in the form of hexagonal phospholipid, or phospholipid from freeze-thawed platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis of the antiphospholipid syndrome\", section on 'Antiphospholipid antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Heparin in the sample",
"    </span>",
"    &nbsp;&mdash;&nbsp;A first step in evaluating an isolated prolonged aPTT or TT is to exclude",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    as the etiology. This is especially important in hospitalized patients, in whom blood is often drawn from heparinized venous access devices. The simplest approach is to redraw a blood sample using an uncontaminated peripheral vein. Alternatively, one can use one of the following two methods:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reptilase time method: perform a thrombin time (TT) and reptilase time (RT).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      is present if the TT is prolonged and the RT is normal.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      reversal method: if a prolonged TT is normalized after the addition of protamine, a commercially available ion exchange resin which absorbs heparin in the sample (Heparsorb), or a heparinase (Hepzyme), heparin or a heparin-like material is present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24727207\">",
"    <span class=\"h1\">",
"     POINT OF CARE TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of coagulation tests can be performed at or near the patient (ie, at the point of care), rather than in a central laboratory, with the rationale that this will result in the rapid generation of results and improve patient care. Such testing includes the following [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/53\">",
"     53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prothrombin time and INR (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35880?source=see_link&amp;anchor=H4#H4\">",
"       \"Outpatient management of oral anticoagulation\", section on 'Self-monitoring and self-management'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Activated partial thromboplastin time",
"     </li>",
"     <li>",
"      Activated clotting time (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Activated whole blood clotting time'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Thrombin time",
"     </li>",
"     <li>",
"      Thromboelastography (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link&amp;anchor=H25#H25\">",
"       \"Platelet function testing\", section on 'Thromboelastography'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Platelet function tests (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link&amp;anchor=H8#H8\">",
"       \"Platelet function testing\", section on 'Platelet aggregometry'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      D-dimer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Point of care testing (POCT) is subject to the same strict quality control procedures that exist in central laboratories; one challenge with POCT is to enforce strict adherence to quality standards outside of the clinical laboratory setting. A discussion of the currently available tests and their limitations has been presented [",
"    <a class=\"abstract\" href=\"UTD.htm?4/36/4682/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/43/28337?source=see_link\">",
"       \"Patient information: Prothrombin time (PT) test and International Normalized Ratio (INR) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A properly drawn blood sample is the key to interpreting the results of clotting tests. The sample must be free of tissue fluids, intravenous solutions delivered through indwelling lines, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      . For sampling from indwelling lines and for difficult-to-obtain samples, especially those obtained by inexperienced personnel, a two-syringe technique is often used (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Obtaining the sample'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The prothrombin time is used to assess the extrinsic pathway of clotting (",
"      <a class=\"graphic graphic_figure graphicRef79998 \" href=\"UTD.htm?23/62/24558\">",
"       figure 1",
"      </a>",
"      ), which consists of tissue factor and factor VII, and coagulation factors in the common pathway (factors II [prothrombin], V, X, and fibrinogen). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prothrombin time'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prothrombin time may be used to monitor therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      and other vitamin K antagonists. This function has been standardized through use of the INR (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Measurement of INR'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      The activated partial thromboplastin time (aPTT or PTT) (",
"      <a class=\"graphic graphic_figure graphicRef79998 \" href=\"UTD.htm?23/62/24558\">",
"       figure 1",
"      </a>",
"      ) is used to assess the integrity of the intrinsic coagulation pathway (prekallikrein, high molecular weight kininogen, factors XII, XI, IX, VIII) and final common pathway (factors II, V, X, and fibrinogen), as well as to monitor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      therapy (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Activated partial thromboplastin time'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The thrombin time (TT) measures the final step of the clotting pathway, the conversion of fibrinogen to fibrin through the addition of exogenous thrombin (",
"      <a class=\"graphic graphic_figure graphicRef79998 \" href=\"UTD.htm?23/62/24558\">",
"       figure 1",
"      </a>",
"      ). The reptilase time is similar to the TT but is insensitive to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      ; this test can be used to rule out heparin as the cause of a prolonged TT. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Thrombin time'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Reptilase time'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Simultaneously drawn prothrombin time (PT) and activated partial thromboplastin time (aPTT) are needed in order to properly evaluate the coagulation system. Under appropriate circumstances, the thrombin time may also need to be obtained. The table outlines the various combinations of test results that may be obtained, and the conditions most likely to cause these changes (",
"      <a class=\"graphic graphic_table graphicRef79969 \" href=\"UTD.htm?42/45/43740\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Evaluation of abnormal clotting times'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For each abnormal test result obtained, mixing the patient's sample in a 1:1 ratio with normal pooled plasma will help to determine if the abnormality is due to a factor deficiency or an inhibitor (see",
"      <a class=\"local\" href=\"#H23\">",
"       'Mixing studies'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the test is corrected, a factor deficiency is present",
"     </li>",
"     <li>",
"      If the test remains abnormal, an inhibitory substance is present",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common inhibitory factor is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , which can be determined by simultaneous thrombin and reptilase times. If the thrombin time is prolonged and the reptilase time is normal, heparin is present in the sample. (see",
"      <a class=\"local\" href=\"#H25\">",
"       'Heparin in the sample'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/1\">",
"      Tripodi A, Chantarangkul V, Mannucci PM. Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing. Br J Haematol 2009; 147:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/2\">",
"      Spaet TH. Case 20-1979: false prolongation of prothrombin time in polycythemia. N Engl J Med 1979; 301:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/3\">",
"      Adcock DM, Kressin DC, Marlar RA. Minimum specimen volume requirements for routine coagulation testing: dependence on citrate concentration. Am J Clin Pathol 1998; 109:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/4\">",
"      Chuang J, Sadler MA, Witt DM. Impact of evacuated collection tube fill volume and mixing on routine coagulation testing using 2.5-ml (pediatric) tubes. Chest 2004; 126:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/5\">",
"      McLaren G, Hanna C, Mills L, et al. Comparison of sampling methods for obtaining accurate coagulation values in hemodialysis patients with heparinized central venous catheters. Nephrol Nurs J 2001; 28:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/6\">",
"      Besley M, Thomas A, Salter S, et al. Control of oral anticoagulation in patients using long-term internal jugular catheters for haemodialysis access. Int J Artif Organs 1992; 15:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/7\">",
"      van Genderen PJ, Gomes M, Stibbe J. The reliability of Hickman catheter blood for the assessment of activation markers of coagulation and fibrinolysis in patients with hematological malignancies. Thromb Res 1994; 73:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/8\">",
"      Delate T, Witt DM, Jones JR, et al. Falsely elevated international normalized ratio values in patients undergoing anticoagulation therapy: a descriptive evaluation. Chest 2007; 131:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/9\">",
"      Gottfried EL, Adachi MM. Prothrombin time and activated partial thromboplastin time can be performed on the first tube. Am J Clin Pathol 1997; 107:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/10\">",
"      Brigden ML, Graydon C, McLeod B, Lesperance M. Prothrombin time determination. The lack of need for a discard tube and 24-hour stability. Am J Clin Pathol 1997; 108:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/11\">",
"      Hirsh J, Poller L. The international normalized ratio. A guide to understanding and correcting its problems. Arch Intern Med 1994; 154:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/12\">",
"      Frith D, Goslings JC, Gaarder C, et al. Definition and drivers of acute traumatic coagulopathy: clinical and experimental investigations. J Thromb Haemost 2010; 8:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/13\">",
"      Perry DJ. Factor VII Deficiency. Br J Haematol 2002; 118:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/14\">",
"      Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:160S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/15\">",
"      Becker DM, Humphries JE, Walker FB 4th, et al. Standardizing the prothrombin time. Calibrating coagulation instruments as well as thromboplastin. Arch Pathol Lab Med 1993; 117:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/16\">",
"      van den Besselaar AM, Poller L, Tripodi A. Guidelines for thromboplastins and plasmas used to control oral anticoagulant therapy. WHO Technical Report Series 1999; 889:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/17\">",
"      Tripodi A, Primignani M, Lemma L, et al. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology 2010; 52:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/18\">",
"      Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997; 127:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/19\">",
"      Robert A, Le Querrec A, Delahousse B, et al. Control of oral anticoagulation in patients with the antiphospholipid syndrome--influence of the lupus anticoagulant on International Normalized Ratio. Groupe M&eacute;thodologie en H&eacute;mostase du Groupe d'Etudes sur l'H&eacute;mostases et la Thrombose. Thromb Haemost 1998; 80:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/20\">",
"      Schmaier AH. Contact activation: a revision. Thromb Haemost 1997; 78:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/21\">",
"      D'Angelo A, Seveso MP, D'Angelo SV, et al. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT. Am J Clin Pathol 1990; 94:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/22\">",
"      Hull RD, Raskob GE, Brant RF, et al. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997; 157:2562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/23\">",
"      JIM RT. A study of the plasma thrombin time. J Lab Clin Med 1957; 50:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/24\">",
"      Mammen EF. Seminars in Thrombosis and Hemostasis. Semin Thromb Hemost 1983; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/25\">",
"      Zehnder JL, Leung LL. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990; 76:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/26\">",
"      Rapaport SI, Zivelin A, Minow RA, et al. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol 1992; 97:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/27\">",
"      Niewiarowski S, Kirby EP, Stocker K. Throbocytin-a novel platelet activating enzyme from Bothrops atrox venom. Thromb Res 1977; 10:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/28\">",
"      Walenga JM, Fasanella AR, Iqbal O, et al. Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost 1999; 25 Suppl 1:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/29\">",
"      Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977; 10:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/30\">",
"      Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114:489S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/31\">",
"      Welsby IJ, McDonnell E, El-Moalem H, et al. Activated clotting time systems vary in precision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass. J Clin Monit Comput 2002; 17:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/32\">",
"      Furuhashi M, Ura N, Hasegawa K, et al. Sonoclot coagulation analysis: new bedside monitoring for determination of the appropriate heparin dose during haemodialysis. Nephrol Dial Transplant 2002; 17:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/33\">",
"      Linkins LA, Julian JA, Rischke J, et al. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res 2002; 107:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/34\">",
"      Marmur JD, Anand SX, Bagga RS, et al. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol 2003; 41:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/35\">",
"      Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb 2003; 33:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/36\">",
"      Gosselin RC, King JH, Janatpour KA, et al. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. Ann Pharmacother 2004; 38:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/37\">",
"      Fenyvesi T, J&ouml;rg I, Harenberg J. Monitoring of anticoagulant effects of direct thrombin inhibitors. Semin Thromb Hemost 2002; 28:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/38\">",
"      Salmela B, Joutsi-Korhonen L, Saarela E, Lassila R. Comparison of monitoring methods for lepirudin: impact of warfarin and lupus anticoagulant. Thromb Res 2010; 125:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/39\">",
"      van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/40\">",
"      el-Sayed MS. Effects of exercise on blood coagulation, fibrinolysis and platelet aggregation. Sports Med 1996; 22:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/41\">",
"      Ogasawara M, Aoki K, Katano K, et al. Activated partial thromboplastin time is a predictive parameter for further miscarriages in cases of recurrent fetal loss. Fertil Steril 1998; 70:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/42\">",
"      Landi G, D'Angelo A, Boccardi E, et al. Venous thromboembolism in acute stroke. Prognostic importance of hypercoagulability. Arch Neurol 1992; 49:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/43\">",
"      Reddy NM, Hall SW, MacKintosh FR. Partial thromboplastin time: prediction of adverse events and poor prognosis by low abnormal values. Arch Intern Med 1999; 159:2706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/44\">",
"      Tripodi A, Chantarangkul V, Martinelli I, et al. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood 2004; 104:3631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/45\">",
"      Aboud MR, Ma DD. Increased incidence of venous thrombosis in patients with shortened activated partial thromboplastin times and low ratios for activated protein C resistance. Clin Lab Haematol 2001; 23:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/46\">",
"      Hron G, Eichinger S, Weltermann A, et al. Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time. J Thromb Haemost 2006; 4:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/47\">",
"      Zakai NA, Ohira T, White R, et al. Activated partial thromboplastin time and risk of future venous thromboembolism. Am J Med 2008; 121:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/48\">",
"      Baccarelli A, Martinelli I, Zanobetti A, et al. Exposure to particulate air pollution and risk of deep vein thrombosis. Arch Intern Med 2008; 168:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/49\">",
"      Lossing TS, Kasper CK, Feinstein DI. Detection of factor VIII inhibitors with the partial thromboplastin time. Blood 1977; 49:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/50\">",
"      Galli M, Finazzi G, Norbis F, et al. The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile. Thromb Haemost 1999; 81:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/51\">",
"      Arnout J, Meijer P, Vermylen J. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I. Thromb Haemost 1999; 81:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/52\">",
"      Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost 1995; 74:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/36/4682/abstract/53\">",
"      Perry DJ, Fitzmaurice DA, Kitchen S, et al. Point-of-care testing in haemostasis. Br J Haematol 2010; 150:501.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1368 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-F0C764AA00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_36_4682=[""].join("\n");
var outline_f4_36_4682=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OBTAINING THE SAMPLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Normal values",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROTHROMBIN TIME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Causes of prolonged PT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Monitoring warfarin therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Measurement of INR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - The INR in liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Monitoring warfarin therapy in the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ACTIVATED PARTIAL THROMBOPLASTIN TIME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Causes of prolonged aPTT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Monitoring heparin therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      THROMBIN TIME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Causes of prolonged TT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Reptilase time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Thrombin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ANTI FACTOR Xa ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ACTIVATED WHOLE BLOOD CLOTTING TIME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      FIBRIN D-DIMER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1023926\">",
"      ECARIN CLOTTING TIME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      EVALUATION OF ABNORMAL CLOTTING TIMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prolonged clotting times",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Shortened clotting times",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Mixing studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Antiphospholipid antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Heparin in the sample",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24727207\">",
"      POINT OF CARE TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1368\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1368|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/62/24558\" title=\"figure 1\">",
"      Coagulation pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/56/27534\" title=\"figure 2\">",
"      Warfarin and clotting proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/42/32429\" title=\"figure 3\">",
"      Self measurement of INR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1368|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/45/43740\" title=\"table 1\">",
"      Causes PT and PTT abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/49/6940\" title=\"table 2\">",
"      Causes elevated D-dimer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=related_link\">",
"      Acquired inhibitors of coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=related_link\">",
"      Acute liver failure in adults: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=related_link\">",
"      Antithrombotic therapy for intracoronary stent implantation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=related_link\">",
"      Approach to the child with bleeding symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26663?source=related_link\">",
"      Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=related_link\">",
"      Coagulation abnormalities in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=related_link\">",
"      Disorders of fibrinogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38120?source=related_link\">",
"      Hemodialysis anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35880?source=related_link\">",
"      Outpatient management of oral anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=related_link\">",
"      Overview of vitamin K",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=related_link\">",
"      Pathogenesis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/43/28337?source=related_link\">",
"      Patient information: Prothrombin time (PT) test and International Normalized Ratio (INR) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=related_link\">",
"      Platelet function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16730?source=related_link\">",
"      Rare (recessively inherited) coagulation disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24022?source=related_link\">",
"      Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21450?source=related_link\">",
"      Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/32/20999?source=related_link\">",
"      Vitamin K, gamma carboxyglutamic acid, and the function of coagulation and other proteins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_36_4683="Severity classification DLCO";
var content_f4_36_4683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Severity classification of diffusing capacity of the lungs for carbon monoxide (DLCO) abnormality",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        &gt;140 percent predicted*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        76 to 140 percent*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild decrease",
"       </td>",
"       <td>",
"        61 to 75 percent*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderate decrease",
"       </td>",
"       <td>",
"        40 to 60 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe decrease",
"       </td>",
"       <td>",
"        &lt;40 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The upper and lower limits of the normal range should be substituted for the 140 and 76 percent predicted cutpoints, if available from a reference study.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_36_4683=[""].join("\n");
var outline_f4_36_4683=null;
var title_f4_36_4684="Multistep approach treatment infertility PCOS";
var content_f4_36_4684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Multistep approach to treatment of anovulatory infertility associated with polycystic ovary syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Step",
"       </td>",
"       <td class=\"subtitle1\">",
"        Intervention",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cost",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk of multiple gestation pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Weight loss (if baseline weight is elevated)",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Not increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Clomiphene",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Modest increase in risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Clomiphene plus adjuvants*",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Modest increase in risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        FSH injections",
"       </td>",
"       <td>",
"        Resource intensive",
"       </td>",
"       <td>",
"        Markedly increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        Ovarian surgery",
"       </td>",
"       <td>",
"        Resource intensive",
"       </td>",
"       <td>",
"        Not increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        In vitro fertilization",
"       </td>",
"       <td>",
"        Resource intensive",
"       </td>",
"       <td>",
"        Potentially increased but controllable (eg, single embryo transfer)&bull;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The initial steps emphasize interventions that are low cost and associated with a low risk of multiple gestation.",
"    <div class=\"footnotes\">",
"     *Most clinicians go directly to FSH injections if clomiphene alone fails. However, the addition of dexamethasone, pretreatment with oral contraceptives, or metformin&nbsp;is an alternative for those who value low cost and low risk of multiple gestation.",
"     <br>",
"      &bull; This increased risk is dependent on the number of embryos transferred.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Barbieri, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_36_4684=[""].join("\n");
var outline_f4_36_4684=null;
var title_f4_36_4685="Clinical symptoms in antisocial personality disorder";
var content_f4_36_4685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F55109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F55109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical symptoms in antisocial personality disorder: Results from a cohort study of 94 patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Men (n = 80)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Women (n = 14)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Total (n = 94)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unstable work history",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        85",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrests",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Financial dependency",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor school history (including truancy)",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        71",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcohol abuse/dependence",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        72",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marital difficulties",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impulsivity",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vagrancy",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Belligerence",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Wild\" adolescence",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Promiscuous sexual behavior",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Social isolation",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of remorse",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use of aliases",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Somatic complaints",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor military performance",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pathological lying",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug abuse/dependence",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suicide attempts",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Percent of sample.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Robins LN. Deviant Children Grown Up. Baltimore: Williams and Wilkins, 1966.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_36_4685=[""].join("\n");
var outline_f4_36_4685=null;
var title_f4_36_4686="MSAFP by gestational age";
var content_f4_36_4686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    The approximate relationship between alpha-fetoprotein (AFP) values in maternal serum and gestational age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 304px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data adapted from: Habib ZA. Maternal Serum alpha-fetoprotein: Its value in antenatal diagnosis of genetic disease and in obstetrical-gynaecological care. Acta Obstet Gynecol Scand 1977;61:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_36_4686=[""].join("\n");
var outline_f4_36_4686=null;
var title_f4_36_4687="Table top test in diabetes";
var content_f4_36_4687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F77892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F77892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Contractures in the metacarpophalangeal joints in diabetes mellitus: Table top test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 113px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Positive table top test in a patient with diabetes (left panel) and a negative test in a normal subject (right panel). The inability to flatten the palm against the surface of a table results from contractures in the metacarpophalangeal joints.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Verna Wright, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_36_4687=[""].join("\n");
var outline_f4_36_4687=null;
